Danaher Corp
DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3027% above fair value
$232.23−4.75 (-2.00%)
Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –
Danaher Cepheid (GeneXpert Molecular Diagnostics) by Year
Cepheid (GeneXpert Molecular Diagnostics) — MAUDE Adverse Event Reports
Danaher Cepheid (GeneXpert Molecular Diagnostics): 43 in FY2025, up 43.3% from a year earlier.
Latest, FY2025
43
Period ended Dec 31, 2025
Change on a year earlier
+43.3%
30 in FY2024
History
9 years
Since FY2017
Sources
1
U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE)
Where the FY2025 figure comes from
Source: U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Reported in U.S. FDA openFDA MAUDE Adverse Event API.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cepheid (GeneXpert Molecular Diagnostics) — MAUDE Adverse Event Reports | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 43 | +43.3% | U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗ |
| FY2024 | Dec 31, 2024 | 30 | +3.4% | U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗ |
| FY2023 | Dec 31, 2023 | 29 | -76.2% | U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗ |
| FY2022 | Dec 31, 2022 | 122 | -72.6% | U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗ |
| FY2021 | Dec 31, 2021 | 446 | – | U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗ |
| FY2019 | Dec 31, 2019 | 0 | -100.0% | U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗ |
| FY2018 | Dec 31, 2018 | 2 | +100.0% | U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗ |
| FY2017 | Dec 31, 2017 | 1 | – | U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗ |
Cite this data
StockData. (2026). Danaher Cepheid (GeneXpert Molecular Diagnostics), annual FY2017–FY2025 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/ext-fda-maude-cepheid
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.